GlassScriptPhysician profile
William John Edmiston
NPI 1053420190
$4,069.34
in general payments reported to CMS, 2019-2025
20 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $387 · 2021: $154 · 2022: $395 · 2023: $406 · 2024: $595 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Travel and Lodging: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.69 |
| Travel and Lodging | $667.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,928.40 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Collegium Pharmaceutical, INC. | $218.60 | 2019-2024 | Belbuca |
| Medtronic, INC. | $125.79 | 2024 | Cd Horizon Spinal System |
| Spr Therapeutics, INC | $117.00 | 2022-2024 | Sprint Pns System |
| Daiichi Sankyo INC. | $109.31 | 2019 | |
| Biodelivery Sciences International, INC. | $80.85 | 2019-2020 | |
| Forte Bio-Pharma LLC | $73.90 | 2019-2020 | |
| Grt US Holding, INC. | $66.67 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Arbor Pharmaceuticals, INC. | $60.75 | 2019 | |
| Scilex Pharmaceuticals INC. | $52.67 | 2019 | |
| Zyla Life Sciences, INC. | $33.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.11 | 2019 | |
| Shionogi INC | $24.62 | 2019 | |
| Terumo Medical Corporation | $16.70 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $14.68 | 2019 | |
| Assertio Therapeutics, INC. | $11.99 | 2020 | |
| Kaleo, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Edmiston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.